The lab has a broad interest in further understanding the molecular basis of prostate cancer (PCa) development and progression in order to identify new therapies for prevention and treatment. The androgen receptor (AR) is required for PCa development, and the standard systemic treatment for PCa is androgen deprivation therapy to suppress AR function. However, patients invariably relapse and AR activity generally persists in these resistant tumors. Therefore, one focus is on molecular biology of AR and mechanisms driving its activity in patients who relapse despite AR targeted therapies. We also have projects related to SOX9, WNT signaling, and apoptotic pathways in PCa. Our studies employ cell line and mouse models, patient derived xenografts, and clinical samples from patients on clinical trials. Depending on experience, students would in most cases initially participate in an ongoing project in collaboration with a senior postdoctoral fellow or junior faculty member, and subsequently develop an aspect of the work into an independent project.